Skip to Content

Ixempra Approval History

  • FDA approved: Yes (First approved October 16th, 2007)
  • Brand name: Ixempra
  • Generic name: ixabepilone
  • Dosage form: Injection
  • Company: Bristol-Myers Squibb
  • Treatment for: Breast Cancer

Ixempra (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with metastatic or locally advanced breast cancer.

Development History and FDA Approval Process for Ixempra

Oct 17, 2007Approval FDA Approves Ixempra (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Jun 19, 2007FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.